
How to Turn Single-Cell Data Into a New Class of Cell-Depleting Therapies
Episode 76
Why treating the cell, not the protein, could turn chronic disease treatment into something closer to a cure. You've built single-cell pipelines that spit out clusters, p-values and target lists, but nothing that survives contact with the clinic. What if the clustering method itself is quietly leading you astray? Adam Freund is Founder and CEO of Arda Therapeutics, a biotech using single-cell sequencing to find the pathogenic cells driving chronic disease. He spent seven years as a Principal Investigator at Calico Life Sciences, building a research lab on the biology of ageing and helping grow the company from 15 to more than 200 people, and holds a PhD in Molecular and Cell Biology from UC Berkeley. You'll get a working model for how Arda's discovery engine turns single-cell and spatial transcriptomic data into causal cell targets. Adam explains why a common statistical shortcut in single-cell analysis produces disease signals that don't hold up and how cell depletion could replace daily dosing with a handful of treatments that reset the immune system. Ross and Adam cover how Arda finds pathogenic cell populations across hundreds of donors, why chi-squared tests on cell clusters can substitute cell count for donor count without anyone noticing, and how B-cell depletion therapies proved that removing a cell can beat blocking its pathway.
Publisher
Data in Biotech
Link
www.corrdyn.com/
Published
August 19, 2026
Duration
54 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
CorrDyn
Data in Biotech
@datainbiotech
#turnsingle #celldata #depletingtherapies #lifesciences
